Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Concert Pharmaceuticals Inc's Business Segments
Concert Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Concert Pharmaceuticals Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- License and Research and Development Revenue100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License and Research and Development Revenue | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Concert Pharmaceuticals Inc
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines to treat patients who are suffering from serious diseases by applying its deuterium chemistry technology. Deuterium is a naturally occurring and stable isotope of hydrogen. This technology enables the company to create new chemical entities with potential advantages across a range of therapeutic areas, including oncology, central nervous system disorders, and inflammation, among others.
The company was founded in 2006 and is headquartered in Lexington, Massachusetts. Its portfolio includes several drug candidates that are either in preclinical or clinical development phases. Their lead program, CTP-543, is an oral drug candidate for the treatment of moderate-to-severe alopecia areata (AA), an autoimmune disease that affects hair growth. It has completed Phase 2a clinical trials and has demonstrated positive results in reducing the severity of AA symptoms.
Another program in concert pharmaceuticals is the AVP-786 program focuses on treating neurologic and psychiatric conditions, such as Alzheimer's disease, schizophrenia, and bipolar disorder. It is a combination of two compounds, dextromethorphan and quinidine. The combination is designed to treat symptoms associated with these conditions by targeting the overactive N-methyl-D-aspartate (NMDA) receptors within the brain.
Concert Pharmaceuticals also has a partnership with Celgene, a subsidiary of Bristol-Myers Squibb, to develop CTP-730, a deuterium-modified version of apremilast. It is an oral medication that works by inhibiting phosphodiesterase 4 (PDE4) and reducing inflammation. The drug is currently in Phase 1 clinical trials for the treatment of moderate-to-severe psoriasis.
The company's approach to drug development is unique and innovative, and it is focused on developing deuterium-modified compounds as a means of improving the properties of molecules to produce safer and more effective drugs. They have received several patents for their deuterium chemistry technology.
Overall, Concert Pharmaceuticals Inc. is a promising biopharmaceutical company with a diverse pipeline of drug candidates that have the potential to transform the treatment of several serious diseases. Its focus on deuterium chemistry technology sets it apart from other pharmaceutical companies and provides an innovative solution to improving drug efficacy and safety.
The company was founded in 2006 and is headquartered in Lexington, Massachusetts. Its portfolio includes several drug candidates that are either in preclinical or clinical development phases. Their lead program, CTP-543, is an oral drug candidate for the treatment of moderate-to-severe alopecia areata (AA), an autoimmune disease that affects hair growth. It has completed Phase 2a clinical trials and has demonstrated positive results in reducing the severity of AA symptoms.
Another program in concert pharmaceuticals is the AVP-786 program focuses on treating neurologic and psychiatric conditions, such as Alzheimer's disease, schizophrenia, and bipolar disorder. It is a combination of two compounds, dextromethorphan and quinidine. The combination is designed to treat symptoms associated with these conditions by targeting the overactive N-methyl-D-aspartate (NMDA) receptors within the brain.
Concert Pharmaceuticals also has a partnership with Celgene, a subsidiary of Bristol-Myers Squibb, to develop CTP-730, a deuterium-modified version of apremilast. It is an oral medication that works by inhibiting phosphodiesterase 4 (PDE4) and reducing inflammation. The drug is currently in Phase 1 clinical trials for the treatment of moderate-to-severe psoriasis.
The company's approach to drug development is unique and innovative, and it is focused on developing deuterium-modified compounds as a means of improving the properties of molecules to produce safer and more effective drugs. They have received several patents for their deuterium chemistry technology.
Overall, Concert Pharmaceuticals Inc. is a promising biopharmaceutical company with a diverse pipeline of drug candidates that have the potential to transform the treatment of several serious diseases. Its focus on deuterium chemistry technology sets it apart from other pharmaceutical companies and provides an innovative solution to improving drug efficacy and safety.
Concert Pharmaceuticals Inc is a biopharmaceutical company headquartered in the United States with a strategic focus on developing innovative medications across various medical fields, primarily centered on the central nervous system (CNS) and inflammation. The companys dedication to producing highly pure drugs with enhanced therapeutic effects positions it to meet diverse patient needs and improve their quality of life.
Segmentation
Concert Pharmaceuticals Inc effectively segments its business based on specific therapeutic areas. The key segments identified include:
1. Central Nervous System (CNS) Disorders: This segment addresses a wide range of neurological and psychiatric disorders. The company targets conditions such as schizophrenia, depression, Alzheimers disease, and narcolepsy, where innovative drug development can significantly impact patient outcomes.
2. Inflammatory Conditions: This segment focuses on immune-related diseases, including autoimmune disorders and conditions like alopecia areata. By using targeted approaches, Concert Pharmaceuticals aims to reduce inflammation and improve functional capabilities in affected patients.
This strategic segmentation allows Concert Pharmaceuticals to tailor its product development and marketing initiatives effectively, ensuring that the solutions they bring to market directly align with the specific needs and characteristics of their target patient populations.
Products and Services
Concert Pharmaceuticals Inc’s portfolio reflects its commitment to delivering innovative treatments that enhance the quality of life for patients. The company’s notable products and services include:
1. CTP-543: A selective JAK1/2 inhibitor designed for the oral treatment of alopecia areata. Currently progressing through phase III clinical trials, CTP-543 has been granted fast track designationby the U.S. FDA, which underscores its potential to meet an urgent medical need in the treatment of this condition. The drug aims to modulate immune responses that lead to hair loss, thereby supporting hair regrowth in affected individuals.
2. CTP-692: This is a deuterated version of risperidone, an established antipsychotic. CTP-692 has shown enhanced pharmacokinetic properties, leading to more efficient dosing regimens. The aim is to achieve a better therapeutic effect with lower dosages, fewer side effects, and prolonged plasma concentration of the medication, making it an appealing option for patients in need of antipsychotic treatment.
3. AVP-786: This innovative product combines two active compounds that target muscarinic and sigma-1 receptors. The goal of AVP-786 is to improve the cognitive and motor functions in patients suffering from schizophrenia, depression, and Alzheimers disease, addressing critical symptoms that affect daily living and mental health.
4. CTP-678: This investigational selective protein kinase C (PKC) inhibitor focuses on mitigating cognitive decline in Alzheimers disease patients. By specifically targeting the hippocampus, which plays a crucial role in learning and memory, CTP-678 holds promise for improving cognitive functions and enhancing the overall quality of life in patients suffering from this debilitating condition.
5. JZP-386: Developed to address cataplexy and excessive daytime sleepiness associated with narcolepsy, JZP-386 aims to provide effective management of these challenging symptoms, allowing individuals to lead more normalized lives.
Collaboration and Innovation
In addition to its internal development programs, Concert Pharmaceuticals Inc actively seeks collaborations with other entities in the biopharmaceutical field. Through these partnerships, the company aims to leverage shared expertise and resources to accelerate the development of its product candidates, thereby expediting the delivery of innovative solutions to patients.
Overall, Concert Pharmaceuticals Inc’s focused approach on CNS and inflammatory conditions, alongside its range of innovative products in development, solidifies its position as a leading biopharmaceutical company committed to advancing patient care through cutting-edge science and targeted therapeutic strategies.
Segmentation
Concert Pharmaceuticals Inc effectively segments its business based on specific therapeutic areas. The key segments identified include:
1. Central Nervous System (CNS) Disorders: This segment addresses a wide range of neurological and psychiatric disorders. The company targets conditions such as schizophrenia, depression, Alzheimers disease, and narcolepsy, where innovative drug development can significantly impact patient outcomes.
2. Inflammatory Conditions: This segment focuses on immune-related diseases, including autoimmune disorders and conditions like alopecia areata. By using targeted approaches, Concert Pharmaceuticals aims to reduce inflammation and improve functional capabilities in affected patients.
This strategic segmentation allows Concert Pharmaceuticals to tailor its product development and marketing initiatives effectively, ensuring that the solutions they bring to market directly align with the specific needs and characteristics of their target patient populations.
Products and Services
Concert Pharmaceuticals Inc’s portfolio reflects its commitment to delivering innovative treatments that enhance the quality of life for patients. The company’s notable products and services include:
1. CTP-543: A selective JAK1/2 inhibitor designed for the oral treatment of alopecia areata. Currently progressing through phase III clinical trials, CTP-543 has been granted fast track designationby the U.S. FDA, which underscores its potential to meet an urgent medical need in the treatment of this condition. The drug aims to modulate immune responses that lead to hair loss, thereby supporting hair regrowth in affected individuals.
2. CTP-692: This is a deuterated version of risperidone, an established antipsychotic. CTP-692 has shown enhanced pharmacokinetic properties, leading to more efficient dosing regimens. The aim is to achieve a better therapeutic effect with lower dosages, fewer side effects, and prolonged plasma concentration of the medication, making it an appealing option for patients in need of antipsychotic treatment.
3. AVP-786: This innovative product combines two active compounds that target muscarinic and sigma-1 receptors. The goal of AVP-786 is to improve the cognitive and motor functions in patients suffering from schizophrenia, depression, and Alzheimers disease, addressing critical symptoms that affect daily living and mental health.
4. CTP-678: This investigational selective protein kinase C (PKC) inhibitor focuses on mitigating cognitive decline in Alzheimers disease patients. By specifically targeting the hippocampus, which plays a crucial role in learning and memory, CTP-678 holds promise for improving cognitive functions and enhancing the overall quality of life in patients suffering from this debilitating condition.
5. JZP-386: Developed to address cataplexy and excessive daytime sleepiness associated with narcolepsy, JZP-386 aims to provide effective management of these challenging symptoms, allowing individuals to lead more normalized lives.
Collaboration and Innovation
In addition to its internal development programs, Concert Pharmaceuticals Inc actively seeks collaborations with other entities in the biopharmaceutical field. Through these partnerships, the company aims to leverage shared expertise and resources to accelerate the development of its product candidates, thereby expediting the delivery of innovative solutions to patients.
Overall, Concert Pharmaceuticals Inc’s focused approach on CNS and inflammatory conditions, alongside its range of innovative products in development, solidifies its position as a leading biopharmaceutical company committed to advancing patient care through cutting-edge science and targeted therapeutic strategies.